ArticleJTO clinical and research reports2023

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors.

Ryo Ariyasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.